Plecanatide Meta-Analysis Finds 3 mg Best Balances Constipation Relief and Safety

A large systematic review and meta-analysis published in BMC Gastroenterology concludes that plecanatide, a guanylate cyclase-C agonist approved by the U.S. Food and Drug Administration in 2017, significantly improves bowel function in adults with chronic idiopathic constipation and irritable bowel syndrome with constipation, with the 3 mg once-daily dose offering the best balance between efficacy and safety. The analysis pooled data from 15 randomized controlled trials covering 15,442 adults, 13 of which entered the quantitative meta-analysis. The work was prospectively registered with PROSPERO under registration number CRD420251066097 and followed PRISMA reporting guidelines and the Cochrane Handbook for Systematic Reviews of Interventions.

The research team, led by Menna M. Aboelkhier and colleagues, searched PubMed, Cochrane CENTRAL, Scopus, Web of Science, and Embase for randomized controlled trials comparing plecanatide with placebo up to August 2025. From 991 records retrieved, 611 remained after duplicate removal, 55 full-text articles were assessed for eligibility, and 15 trials were ultimately included in the systematic review. No additional studies emerged from manual reference-list screening. Most participants were female, accounting for 63.1 percent of the pooled population, and most were aged between 18 and 50 years. Baseline abdominal pain scores averaged 4.13 in treatment groups and 4.20 in controls, while baseline complete spontaneous bowel movements averaged roughly two per week in both arms.

Plecanatide works through a mechanism that mirrors a natural gut hormone. It is a synthetic 16-amino acid peptide structurally similar to uroguanylin, an endogenous activator of guanylate cyclase-C receptors on intestinal epithelial cells. Binding these receptors raises intracellular cyclic guanosine monophosphate, which stimulates chloride and bicarbonate secretion through cystic fibrosis transmembrane conductance regulator channels. The resulting increase in intestinal fluid secretion softens stool and accelerates transit, and the drug shows minimal systemic absorption. The discussion section of the paper adds that cyclic guanosine monophosphate inhibits the luminal sodium-hydrogen exchanger NHE3 and indirectly stimulates CFTR through phosphorylation, collectively improving intestinal fluid balance.

The headline efficacy finding concerns complete spontaneous bowel movements, the primary endpoint. Compared with placebo, plecanatide significantly increased weekly changes in complete spontaneous bowel movements at four of the five tested doses: 1 mg produced a mean difference of 0.75 (95 percent confidence interval 0.66 to 0.84), 3 mg produced 0.92 (0.69 to 1.14), 6 mg produced 0.80 (0.66 to 0.95), and 9 mg produced 1.00 (0.55 to 1.44), all with P values below 0.00001. The lowest dose, 0.3 mg, showed no significant change overall, with a mean difference of 0.25 and a confidence interval crossing zero. However, a subgroup analysis restricted to chronic idiopathic constipation studies found that even 0.3 mg produced a significant improvement of 0.42, while the single irritable bowel syndrome study at that dose showed essentially no effect.

Spontaneous bowel movements improved significantly at the 1, 3, and 6 mg doses, with mean differences of 0.97, 1.50, and 1.58 respectively, each reaching statistical significance at P below 0.00001. The 0.3 mg dose also increased spontaneous bowel movements with a mean difference of 0.67. Stool consistency, measured on the Bristol Stool Form Scale, improved significantly at every dose tested, with the largest effect at 9 mg (mean difference 1.09) and effects ranging from 0.44 to 0.76 at the other doses. Straining scores improved significantly only at 3 mg and 6 mg, with mean differences of −0.51 and −0.55, while the 0.3, 1, and 9 mg doses showed no significant benefit for this outcome.

Abdominal symptoms showed a dose-dependent pattern. The 3 mg dose significantly reduced both abdominal pain (mean difference −0.40, P = 0.003) and bloating (mean difference −0.22, P below 0.00001), whereas the 6 mg dose improved bloating (mean difference −0.22, P = 0.007) but not pain (P = 0.06). Direct comparisons between the 3 mg and 6 mg doses showed no significant differences for these symptoms. The analysis also captured rapid onset of action: within 24 hours of treatment initiation, both 3 mg and 6 mg significantly increased the proportion of patients achieving at least one complete spontaneous bowel movement (risk ratios 1.79 and 1.93) or one spontaneous bowel movement (risk ratios 1.36 and 1.39) compared with placebo, with low heterogeneity across studies.

Dose-to-dose comparisons revealed a therapeutic plateau. The 1 mg and 9 mg doses both outperformed 0.3 mg for complete spontaneous bowel movements, with mean differences of 0.63 and 1.16 respectively, but no significant differences emerged among the higher doses in comparisons of 1 versus 3 mg, 3 versus 6 mg, or 9 versus 3 mg. For spontaneous bowel movements, 1 mg significantly outperformed 0.3 mg, while 3 mg and 6 mg did not differ. The authors interpret this pattern as evidence that increasing the dose beyond roughly 1 mg per day does not yield proportionally greater bowel-function benefit, a plateau they say helps delineate the threshold beyond which additional dosing may not translate into clinically meaningful improvement.

Safety findings complicate the picture in a dose-related way. Diarrhea was the most frequent adverse event and the primary reason for treatment discontinuation, occurring more often with every plecanatide dose than with placebo, an effect the authors link mechanistically to excessive guanylate cyclase-C–driven fluid secretion. Treatment-emergent adverse events of any kind were significantly more common with plecanatide at 1 mg (risk ratio 1.55), 3 mg (1.27), 6 mg (1.12), and 9 mg (2.48) compared with placebo, while the 0.3 mg dose showed no significant increase. Patients receiving 3 mg or 6 mg withdrew from treatment more frequently than those on placebo. However, serious or severe adverse events did not differ significantly from placebo at either dose, and plecanatide was not associated with increased headache or nasopharyngitis at any dose. Adverse events reported by at least 1 percent of patients were not significantly elevated at any dose.

The certainty of the evidence, graded using the GRADE framework, varied considerably by outcome. High-certainty evidence supported the overall sustained responder outcome and the 24-hour response measures for both bowel movement types. Moderate-certainty evidence covered spontaneous bowel movements, stool consistency, straining, abdominal pain, bloating, constipation severity, diarrhea, and other adverse events. Low-certainty evidence applied to changes in complete spontaneous bowel movements, overall treatment-emergent adverse events, serious or severe events, and withdrawals, largely because of risk-of-bias concerns including randomization, blinding, incomplete outcome data, and selective reporting. Very low certainty applied to adverse events reported in at least 1 percent of participants. The risk-of-bias assessment using the Cochrane ROB 2 tool found that most studies had a high risk of bias, mainly due to missing outcome data, though five trials were rated low risk across all domains.

The authors conclude that plecanatide is generally well tolerated and effective for chronic idiopathic constipation and irritable bowel syndrome with constipation, with the 3 mg once-daily dose providing the most consistent balance between efficacy and safety. They note limitations including gray literature in the evidence base, substantial heterogeneity in several symptom-based outcomes, limited data for certain doses, and variability in adverse event reporting. They call for future large-scale, well-designed randomized controlled trials to confirm long-term efficacy and safety, evaluate underexplored dosing regimens, and define plecanatide’s role in comparison or combination with other therapies. The findings arrive against a backdrop in which chronic idiopathic constipation affects roughly 14 percent of the global population under Rome IV criteria and irritable bowel syndrome with constipation affects an estimated 4 to 10 percent, conditions that carry quality-of-life burdens comparable to chronic inflammatory diseases and substantial healthcare costs.

Subject of Research: Efficacy and safety of plecanatide across doses in chronic idiopathic constipation and irritable bowel syndrome with constipation

Article Title: Gut relief revisited: plecanatide in chronic idiopathic constipation and irritable bowel syndrome with constipation — a systematic review and meta-analysis with GRADE assessment

Article References: Aboelkhier, M. M., Elnaggar, I. S., Elsamahy, N. Y., Breim, F., Youssef, A. A., & Alsayed, A. R. (2026). Gut relief revisited: plecanatide in chronic idiopathic constipation and irritable bowel syndrome with constipation — a systematic review and meta-analysis with GRADE assessment. BMC Gastroenterology, 26(1), Article 703. https://doi.org/10.1186/s12876-026-05112-w

Image Credits: AI Generated

DOI: 10.1186/s12876-026-05112-w

Keywords: plecanatide, chronic idiopathic constipation, irritable bowel syndrome with constipation, meta-analysis, guanylate cyclase-C agonist, randomized controlled trials, GRADE assessment, diarrhea, dose-response, Bristol Stool Form Scale, systematic review, gastroenterology